Patents by Inventor Naomi Galili

Naomi Galili has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Terminal erythroid differentiation as a biomarker for prognosis and treatment, and therapeutic target in myeloid malignancies
    Patent number: 11186877
    Abstract: The present invention relates to utilizing terminal erythroid differentiation (TED) as a biomarker for prognosis and as a therapeutic target in myeloid malignancies, in particular myelodyplastic syndromes. The present invention relates to identifying patients with myelodysplastic syndromes at risk for poor survival/outcomes who would benefit from aggressive treatment, by characterizing their TED profile using protein and gene expression markers and combinations thereof.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: November 30, 2021
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Azra Raza, Abdullah Mahmood Ali, Naomi Galili
  • TERMINAL ERYTHROID DIFFERENTIATION AS A BIOMARKER FOR PROGNOSIS AND TREATMENT, AND THERAPEUTIC TARGET IN MYELOID MALIGNANCIES
    Publication number: 20190187159
    Abstract: The present invention relates to utilizing terminal erythroid differentiation (TED) as a biomarker for prognosis and as a therapeutic target in myeloid malignancies, in particular myelodyplastic syndromes. The present invention relates to identifying patients with myelodysplastic syndromes at risk for poor survival/outcomes who would benefit from aggressive treatment, by characterizing their TED profile using protein and gene expression markers and combinations thereof.
    Type: Application
    Filed: December 18, 2018
    Publication date: June 20, 2019
    Inventors: Azra Raza, Abdullah Mahmood Ali, Naomi Galili
  • Compositions and diagnostic kits for identifying alveolar rhabdomyosarcoma
    Patent number: 5650278
    Abstract: Methods of determining whether a tumor is an alveolar rhabdomyosarcoma tumor by detecting the presence of a DNA sequence of a chimeric gene that is generated by translocation of a portion of human chromosome 2 and a portion of human chromosome 13 are disclosed. In addition, diagnostic kits to practice methods of determining whether a tumor is an alveolar rhabdomyosarcoma tumor are disclosed. Isolated nucleic acid molecules which comprise nucleotide sequences that are complementary to at least a portion of human chromosome 2 or a portion of human chromosome 13 are disclosed.
    Type: Grant
    Filed: October 25, 1994
    Date of Patent: July 22, 1997
    Assignees: Children's Hospital of Philadelphia, Trustees of The University of Pennsylvania, The Wistar Institute of Anatomy and Biology
    Inventors: Frederic G. Barr, Beverly S. Emanuel, Naomi Galili